Ligand validation:5JES

EVF: 1,3-benzothiazole-2-sulfonamide

EVF is a Ligand Of Interest in 5JES designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5JES_EVF_B_302	88%	2%	0.097	0.972	4.37	2.42	1	4	1	0	100%	0.45
5JES_EVF_B_303	10%	1%	0.204	0.709	4.83	2.73	2	6	0	0	100%	0.37
5JDV_EVF_B_302	99%	27%	0.063	0.994	0.95	1.95	-	7	0	0	100%	1
5JEG_EVF_B_302	98%	17%	0.065	0.991	1.07	2.52	-	4	0	0	100%	0.96
5JG3_EVF_B_301	98%	22%	0.066	0.992	1.28	1.95	1	6	0	0	100%	1
5JEP_EVF_B_302	98%	27%	0.07	0.995	1.12	1.8	1	5	0	0	100%	1
5JE7_EVF_B_302	98%	28%	0.07	0.994	0.99	1.85	1	5	0	0	100%	1
5JG5_EVF_B_301	97%	33%	0.081	0.994	0.96	1.65	-	3	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.